Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735
Go back to Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 37.26 +2.45 (7.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.81 | 52 Week High | $5.17 | |||
| Open | $35.63 | 52 Week Low | $0.94 | |||
| Day High | $37.86 | P/E | N/A | |||
| Day Low | $35.03 | EPS | $0.00 | |||
| Volume | 3,613,363 | |||||
